UK’s New Clinical Trial Law Takes Effect: Faster Review for Low-Risk Studies, Alongside Higher Transparency Obligations

Whether a drug trial can begin early depends not only on its scientific design, but is also often held up at the intersection of regulatory and ethics review. From April 28, 2026, the UK will implement its largest clinical trial regulatory reform in more than two decades, seeking to adjust the intensity of review according to risk while enshrining research transparency and participants’ right to be informed in law.

The new system formally establishes in law the joint review process conducted by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and research ethics committees, and creates a notification mechanism for eligible low-risk applications and amendments. For substantial amendments that do not introduce new safety concerns, the “Route B” procedure provides that an application is automatically approved if the competent authority raises no concerns within 14 calendar days; during the previous pilot period, the average processing time was 7 days.

The reform also broadens the forms of evidence that regulators may consider, including overseas early-stage safety data that meet UK standards and computer simulations used to predict how a drug will perform in humans. This does not mean that models can replace human trials, but rather allows reviewers to integrate more preliminary evidence when making decisions about first-in-human trials and dosing strategies.

Beyond speed, the new law gives greater prominence to public accountability. In principle, clinical trials of medicines must be registered on a public registry, with a summary of results published within 12 months of completion. Research teams must also provide participants with an easy-to-understand version of the results, although deferral provisions may apply to certain studies. If the first UK participant has still not been recruited within two years of approval, the approval may lapse unless an extension has been obtained in advance.

The composition of research teams is also more flexible. Pharmacists, nurses, midwives, and certain regulated healthcare professionals who meet qualification and training requirements may now serve as investigators or chief investigators. Trial sponsors must still confirm that their education, experience, and scientific background are sufficient for the role. If an investigator is not a physician or dentist, work involving medical care and medical judgment must still be provided or supervised by a qualified person.

The boundary between the old and new systems is more complex. For trials submitted before April 28, applications will generally continue to be reviewed under the old rules; submissions made after that date will be subject to the new rules. The applicable rules for a substantial amendment are determined by the amendment application’s submission date, rather than when the original trial began. If a trial under the old system ends only after the new law takes effect, it must still complete public registration and disclose a summary of results, but providing participants with an easy-to-read summary is not mandatory. Investigational medicinal products manufactured or imported after the effective date will generally also need to comply with the new system’s requirements.

The authorities said that the overall setup time for commercial trials undergoing combined safety and ethics review has fallen from 169 days to 122 days, with the regulatory and ethics reviews themselves taking an average of 41 days. However, these figures encompass process improvements introduced before the reform and cannot by themselves demonstrate the new law’s effectiveness. Whether the new system can balance speed, review quality, and participant protection will still need to be assessed collectively through post-implementation approval times, safety events, recruitment performance, and compliance rates for results disclosure.